ScreenerHero

RAREUltragenyx Pharmaceutical Inc.

NAS · US · Healthcare · Biotechnology · ultragenyx.com
25.83USD-1.56%Mkt Cap: 2.55B $P/E: —

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in N…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap2.55B $
Enterprise Value3.41B $
Revenue (TTM)717.00M $
Gross Profit564.00M $
Net Income (TTM)-575.00M $
Revenue/Share7.131 USD
Last Price25.83 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees1.4K
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)38.04
PEG—
EV/EBITDA-7.32
EV/Revenue4.75
P/S3.48
P/B-8.55
EPS (TTM)-5.63
EPS (Forward)0.67
52W Range
18.2935% of range39.89
52W High39.89 USD
52W Low18.29 USD
Profitability
Gross Margin83.80%
Oper. Margin-35.05%
EBITDA Margin-64.85%
Profit Margin-85.44%
ROE718.75%
ROA-37.53%
Growth
Revenue Growth28.10%
Earnings Growth—
Cash Flow & Leverage
Operating CF-466.00M $
CapEx (TTM)21.00M $
FCF Margin-25.08%
FCF Yield-7.06%
Net Debt910.00M $
Net Debt/EBITDA-1.96
Balance Sheet
Debt/Equity-0.45
Current Ratio1.73
Quick Ratio1.41
Book Value/Sh-2.9600 USD
Cash/Share2.971 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)54.21 USD
Upside (mean)+109.9%
Target Range28.00 USD – 103.00 USD
$28.00+109.9% to mean$103.00
# Analysts19
Ownership
Shares Out.98.59M
Float80.42M
Insiders3.44%
Institutions111.88%
Short Interest
Short Ratio7.1d
Short % Float15.70%
Short % Out.15.18%
Shares Short14.96M
Short (prev mo.)16.22M
Technical
SMA 5028.27 (-8.6%)
SMA 20026.46 (-2.4%)
Beta0.31
S&P 52W Chg18.16%
Avg Vol (30d)1.73M
Avg Vol (10d)2.18M
Technical Indicators
RSI (14)42.4
MACD-0.5643
MACD Signal-0.6404
MACD Hist.+0.0761
BB Upper27.52 USD
BB Middle26.10 USD
BB Lower24.67 USD
BB Width10.91%
ATR (14)1.305 USD
Vol Ratio (20d)1.26x